HOUSTON, Jan. 9, 2013 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ:CYBX) today announced that Bruce H. KenKnight, Ph.D., joined the company as its Vice President, Emerging Therapies, effective on January 1, 2013. Dr. KenKnight will lead all of the company's emerging therapies programs, including the current clinical evaluation of Autonomic Regulation Therapy , an emerging therapy for treatment of chronic heart failure that incorporates Cyberonics' extensive experience delivering vagus nerve stimulation to more than 100,000 patients world-wide.
Most recently, Dr. KenKnight was President and CEO of Valtech Cardio Ltd, a privately-held company developing innovative solutions for surgical and percutaneous mitral valve repair and replacement. For the 20-year period ending in 2010, he worked at Boston Scientific Corporation (formerly Guidant Corporation), finally serving as Vice President of Research and Business Development for the Cardiac Rhythm Management Division. Dr. KenKnight has served on the Board of Directors of seven privately-held companies and is an author of more than 150 peer-reviewed manuscripts, reviews, book chapters and conference abstracts in fields relating to cardiac electrophysiology and heart failure. He is an editorial consultant for several cardiology journals and serves as Associate Editor for Cardiovascular Engineering and Technology. In 2006, Dr. KenKnight received the Albert Einstein Award for Outstanding Achievement in the Life Sciences from the Global Business Leadership Council in Tel Aviv, Israel. In 2007, he was elected to the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). Dr. KenKnight is also an Adjunct Professor of Biomedical Engineering at the University of Minnesota and is named as an inventor on more than 120 U.S. patents and more than 250 patents world-wide.
"Bruce has 30 years of experience developing high-value solutions to address major unmet medical needs and has consistently demonstrated the ability to drive innovative programs that lead to substantial shareholder value," said Dan Moore, Cyberonics' President and Chief Executive Officer. "We enthusiastically welcome Bruce to the Cyberonics team and look forward to continued progress on our emerging therapy programs, facilitating the substantial, long-term growth of the company," said Milton Morris, Ph.D., Senior Vice President, Research and Development.
Bruce received the Bachelor of Science degree in mechanical engineering, Master of Science and Ph.D. degrees in biomedical engineering from the College of Science & Technology at the University of Minnesota in Minneapolis, and has completed business management training at the Harvard School of Business, University of Chicago and the Kellogg School of Management.About Cyberonics, Inc. and the VNS Therapy ® System Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation. The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses an implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV